<SEC-DOCUMENT>0001764013-25-000024.txt : 20250206
<SEC-HEADER>0001764013-25-000024.hdr.sgml : 20250206
<ACCEPTANCE-DATETIME>20250206063753
ACCESSION NUMBER:		0001764013-25-000024
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250206
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250206
DATE AS OF CHANGE:		20250206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunovant, Inc.
		CENTRAL INDEX KEY:			0001764013
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				832771572
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38906
		FILM NUMBER:		25595364

	BUSINESS ADDRESS:	
		STREET 1:		320 WEST 37TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018
		BUSINESS PHONE:		917-580-3099

	MAIL ADDRESS:	
		STREET 1:		320 WEST 37TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Health Sciences Acquisitions Corp
		DATE OF NAME CHANGE:	20190108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>imvt-20250206.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5236f04c-de75-4016-94d7-a14c75e168f0,g:d73988aa-885e-40a5-9fd8-a2558c6ef7c7,d:215223e353bb4295a7a1960f251d1ada-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>imvt-20250206</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001764013</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="imvt-20250206.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-06</xbrli:startDate><xbrli:endDate>2025-02-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i215223e353bb4295a7a1960f251d1ada_1"></div><div style="min-height:18.39pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-right:-0.07pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:12pt;padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;padding-left:0.4pt;padding-right:0.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 6, 2025</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">IMMUNOVANT, INC.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-right:-0.07pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.190%"><tr><td style="width:1.0%"/><td style="width:19.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.294%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38906</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">83-2771572</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:106%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(IRS Employer Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">320 West 37th Street</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">New York,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">10018</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">917</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">580-3099</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;padding-left:0.2pt;padding-right:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:12pt;padding-left:0.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.476%"><tr><td style="width:1.0%"/><td style="width:36.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.702%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.426%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.153%"/><td style="width:0.0%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.5pt;padding-right:2.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">IMVT</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;padding-left:0.2pt;padding-right:15pt"><span><br/></span></div><div style="padding-right:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:0.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;padding-left:0.2pt;padding-right:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i215223e353bb4295a7a1960f251d1ada_7"></div><hr style="page-break-after:always"/><div style="min-height:13.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 6, 2025, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal third quarter and nine months ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.670%"><tr><td style="width:1.0%"/><td style="width:14.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit9912025206.htm">Press release, dated February 6, 2025.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i215223e353bb4295a7a1960f251d1ada_10"></div><hr style="page-break-after:always"/><div style="min-height:13.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.945%"><tr><td style="width:1.0%"/><td style="width:55.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.419%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IMMUNOVANT, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Eva Renee Barnett</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Eva Renee Barnett</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date: February 6, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit9912025206.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4b1836a0fd11441c9ab53a830b94dea4_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:14.95pt;padding-left:25.12pt;padding-right:25.12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Immunovant Reports Financial Results for the Quarter Ended December 31, 2024</font></div><div style="margin-top:0.45pt;padding-left:36pt;padding-right:12.7pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;padding-right:12.7pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%;padding-left:14.15pt">Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves&#8217; disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector</font></div><div style="margin-top:0.45pt;padding-left:36pt;padding-right:12.7pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;padding-right:12.7pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%;padding-left:14.15pt">Additional results from batoclimab proof-of-concept study in GD, including 6-month treatment free remission data expected in summer 2025</font></div><div style="margin-top:0.45pt;padding-left:36pt;padding-right:12.7pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;padding-right:12.7pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%;padding-left:14.15pt">Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025</font></div><div style="margin-top:0.45pt;padding-left:36pt;padding-right:12.7pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;padding-right:12.7pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%;padding-left:14.15pt">Pro forma cash balance of approximately $825 million as of December 31, 2024, including approximately $450 million gross proceeds from a private placement that closed on January 15, 2025</font></div><div style="margin-top:0.35pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NEW YORK, Feb. 6, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq&#58; IMVT)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.</font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We are energized by the progress of our IMVT-1402 development plans, with six INDs now cleared and all clinical studies to be conducted using standard YpsoMate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> autoinjector technology and our planned commercial formulation,&#8221; said Pete Salzmann, M.D., chief executive officer of Immunovant.  &#8220;We continue to expect to share the top line results from our batoclimab pivotal study in MG and period one results from our study in CIDP by the end of this quarter, and anticipate these results being used to further optimize our development plans for our potentially best-in-class lead asset, IMVT-1402.&#8221; </font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:0.45pt;padding-right:12.7pt"><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:119%">Recent Highlights and Upcoming Milestones</font></div><div style="margin-top:0.45pt;padding-right:12.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Immunovant continues to focus on moving rapidly to unlock the full potential of its lead asset, IMVT-1402, for the benefit of people with underserved autoantibody-driven diseases.  As previously announced, Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026.&#160;</font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:0.45pt;padding-right:12.7pt"><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:119%">Endocrinology Program</font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Immunovant recently initiated the first potentially registrational trial of the company&#8217;s lead asset, IMVT-1402, in adult participants with GD who are hyperthyroid despite antithyroid drug (ATD) treatment. This study builds on the batoclimab proof-of-concept data presented in 2024, which suggest the potential for deep IgG reduction in the treatment of GD for patients who are not well controlled on ATDs. </font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Immunovant also plans to announce additional data from the batoclimab proof-of-concept study in GD including 6-month, treatment-free remission data designed to further articulate potential for IMVT-1402 in GD.  These data are expected in the summer of 2025.</font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Top-line results from the pivotal program of batoclimab for the treatment of thyroid eye disease (TED), also known as Graves' ophthalmopathy, continue to be expected in the second half of calendar year 2025, along with a decision whether to pursue marketing authorization for batoclimab in TED.  Data from this trial may also inform the IMVT-1402 program in GD.</font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:0.45pt;padding-right:12.7pt"><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:119%">Neurology Program</font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Immunovant intends to report top-line results from the pivotal trial of batoclimab in MG by March 31, 2025. Results from this trial are expected to inform a decision regarding next steps for batoclimab in MG and inform the design of a potentially registrational program for IMVT-1402 in MG, which Immunovant expects to initiate following the disclosure of the batoclimab data in MG.</font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Results from period one of the trial evaluating batoclimab in CIDP continue to be expected by March&#160;31, 2025. Those results, as well as observations drawn from public disclosures of other studies in CIDP, are expected to inform a potentially registrational program for IMVT-1402 in CIDP, which Immunovant expects to initiate following the disclosure of the batoclimab CIDP data.</font></div><div style="margin-top:0.45pt;padding-right:12.7pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:0.45pt;padding-right:12.7pt"><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:119%">Rheumatology Program</font></div><div style="margin-bottom:15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Immunovant recently initiated a potentially registrational trial of IMVT-1402 in adult participants with active, anti-citrullinated protein autoantibody (ACPA) positive difficult-to-treat rheumatoid arthritis. The trial includes IMVT-1402&#8217;s higher dose (600 mg) as recent in-class data suggest that deeper ACPA reduction correlated with better clinical improvement in ACPA+ RA patients treated with an FcRn inhibitor.</font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Highlights for Fiscal Third Quarter Ended December 31, 2024</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Position&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As of December 31, 2024, Immunovant&#8217;s cash and cash equivalents totaled $374.7 million.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D Expenses&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Research and development expenses were $94.5 million for the three months ended December 31, 2024, compared to $48.3 million for the three months ended December 31, 2023. The increase was primarily due to activities in preparation for potential future clinical trials of IMVT-1402, including contract manufacturing costs, elevated personnel-related expenses and higher overall clinical trial costs related to our batoclimab pivotal clinical trials. The increase was partially offset by lower overall costs related to our IMVT-1402 Phase 1 trial and nonclinical studies.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> General and administrative expenses were $19.8 million for the three months ended December 31, 2024, compared to $13.2 million for the three months ended December 31, 2023. The increase was primarily due to higher personnel-related expenses, legal and other professional fees, information technology costs and market research costs.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net loss was $111.1 million ($0.76 per common share) for the three months ended December 31, 2024, compared to $51.4 million ($0.36 per common share) for the three months ended December 31, 2023. Net loss for the three months ended December 31, 2024 and December 31, 2023 included $11.7 million and $10.2 million, respectively, related to non-cash stock-based compensation expense.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Stock&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As of December 31, 2024, there were 147,203,565 shares of common stock issued and outstanding.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Highlights for Fiscal Nine Months Ended December 31, 2024</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D Expenses&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Research and development expenses were $267.3 million for the nine months ended December 31, 2024, compared to $146.9 million for the nine months ended December 31, 2023. The increase was primarily due to activities in preparation for potential future clinical trials of IMVT-1402, including contract manufacturing costs, elevated personnel-related expenses and higher overall clinical trial costs related to our batoclimab pivotal clinical trials. The increase was partially offset by lower overall costs related to our IMVT-1402 Phase 1 trial and nonclinical studies.</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IPR&#38;D Expenses&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no acquired in-process research and development expenses for the nine months ended December 31, 2024.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended December 31, 2023, acquired in-process research and development expenses were $12.5 million related to the achievement of development and regulatory milestones for batoclimab under the terms of the HanAll in-license agreement.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> General and administrative expenses were $57.1 million for the nine months ended December 31, 2024, compared to $42.5 million for the nine months ended December 31, 2023. The increase was primarily due to higher personnel-related expenses, legal and other professional fees, information technology costs and market research costs.</font><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net loss was $307.4 million ($2.10 per common share) for the nine months ended December 31, 2024, compared to $184.0 million ($1.36 per common share) for the nine months ended December 31, 2023. Net loss for the nine months ended December 31, 2024 and December 31, 2023 included $37.8 million and $31.4 million, respectively, related to non-cash stock-based compensation expense.</font></div><div style="padding-left:8pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:8pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Immunovant, Inc.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:4.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company  is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%;text-decoration:underline">immunovant.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:119%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;design,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include statements regarding Immunovant&#8217;s expectations regarding the timing, design, and results of clinical trials of IMVT-1402 and batoclimab, including the number and timing of (a) FDA clearance with respect to IND applications, (b) potential registrational programs and clinical trials of IMVT-1402, (c) expected data readouts from batoclimab trials in MG and CIDP, and (d) Immunovant&#8217;s plan to develop IMVT-1402 across a broad range of indications&#59; and potential benefits of IMVT-1402&#8217;s unique product attributes and potential best-in-class profile. All forward-looking statements are based on estimates and assumptions by Immunovant&#8217;s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others&#58; Immunovant may not be able to protect or enforce its intellectual property rights&#59; initial results or other preliminary analyses or results of early clinical trials may not be predictive of final trial results or of the results of later clinical trials&#59; the timing and availability of data from clinical trials&#59; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals&#59; the continued development of Immunovant&#8217;s product candidates, including the number and timing of the commencement of additional clinical trials&#59; Immunovant&#8217;s scientific approach, clinical trial design, indication selection, and general development progress&#59; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release&#59; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all&#59; Immunovant&#8217;s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized&#59; the potential impact of macroeconomic and geopolitical factors on Immunovant&#8217;s business operations and supply chain, including its clinical development plans and timelines&#59; Immunovant&#8217;s business is heavily dependent on the successful development, regulatory approval, and commercialization of IMVT-1402 and&#47;or batoclimab&#59; Immunovant is at various stages of clinical development for IMVT-1402 and batoclimab&#59; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant&#8217;s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled &#8220;Risk Factors&#8221; in Immunovant&#8217;s Form 10-Q to be filed with the SEC on February 6, 2025, and Immunovant&#8217;s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;text-align:center"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">IMMUNOVANT, INC. </font></div><div style="margin-top:0.05pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Condensed Consolidated Statements of Operations </font></div><div style="margin-top:0.05pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">(Unaudited, in thousands, except share and per share data)</font></div><div style="margin-top:0.05pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-right:-0.38pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</font></div><div style="margin-bottom:1.5pt;padding-right:-0.38pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-right:-0.38pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended</font></div><div style="margin-bottom:1.5pt;padding-right:-0.38pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.62pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$94,520</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$48,338</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$267,266</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$146,872</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.62pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,500</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.62pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,782</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,215</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,061</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,458</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.38pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,302</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,553</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">324,327</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201,830</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,590)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,933)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,844)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,569)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,258</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,094)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,579)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision (benefit) for income taxes</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(110,970)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51,526)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(307,083)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(183,682)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">308</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">335</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$(111,122)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$(51,418)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$(307,391)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$(184,017)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8211; basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$(0.76)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$(0.36)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$(2.10)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$(1.36)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8211; basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,922,338</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,523,034</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,560,414</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.62pt;padding-right:-1.88pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,577,267</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">IMMUNOVANT, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Condensed Consolidated Balance Sheets </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">(Unaudited, in thousands, except share and per share data)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">March 31, 2024</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Assets</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current assets&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">374,685&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">635,365&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts receivable</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,224</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,337</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prepaid expenses and other current assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">35,632</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">25,068</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total current assets</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">412,541</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">665,770</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating lease right-of-use assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">22</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">133</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,617</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment, net</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">752</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">462</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total assets</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">420,932</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">666,365</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current liabilities&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts payable</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19,816&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,155&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accrued expenses</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">48,476</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41,315</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current portion of operating lease liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">138</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total current liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68,315</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">48,608</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68,315</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">48,608</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Commitments and contingencies</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stockholders&#8217; equity&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at December 31, 2024 and March 31, 2024</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2024 and March 31, 2024</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 147,203,565 shares issued and outstanding at December 31, 2024 and 500,000,000 shares authorized, 145,582,999 shares issued and outstanding at March 31, 2024</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional paid-in capital</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,483,198</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,441,518</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accumulated other comprehensive income</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,479</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,908</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accumulated deficit</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,133,074)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(825,683)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stockholders&#8217; equity</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">352,617</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">617,757</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">420,932</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">666,365</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Renee Barnett, MBA  </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Chief Financial Officer  </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Immunovant, Inc.  </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">info&#64;immunovant.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Source&#58; Immunovant Inc.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>imvt-20250206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5236f04c-de75-4016-94d7-a14c75e168f0,g:d73988aa-885e-40a5-9fd8-a2558c6ef7c7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:imvt="http://immunovant.com/20250206" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://immunovant.com/20250206">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imvt-20250206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imvt-20250206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://immunovant.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>imvt-20250206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5236f04c-de75-4016-94d7-a14c75e168f0,g:d73988aa-885e-40a5-9fd8-a2558c6ef7c7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5dfb5968-4489-4f36-9504-9ccc4bf618a7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_19181d17-b6d0-4b2d-983b-8b1317a155be_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3f14a9c6-2590-4fc6-82f0-301cebe9f71d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a29ea574-e9e2-40fc-81c2-e7b519a8f17a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f68fee21-98bf-422b-be70-eb4a1709d207_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f7b0a2f6-2a32-48cc-8448-d58e57cc9ba0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ec98a063-81af-4157-ae5e-145dd04f3c78_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3e4ef037-f49e-446c-9739-9707b7b8d6dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_8f143ab3-c929-4eb0-984f-f6b5e3e6c977_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e5e7b90e-93a4-4db1-a4b1-a4dcf2e9fec5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_657d5de6-6739-4c38-8d04-6cc9e2a96853_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_341e7775-8705-498a-b231-1dbe3f9ca180_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_292d6867-3c94-4c96-bfdc-7e5e4901910b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c00bcb85-fd93-4e33-8c7a-5a9c090ffa72_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b8ca73ca-b79e-49d1-bc19-095baf237c74_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e2697189-ec01-4cc5-8c0e-6610045cd071_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f73fdcb2-8b46-4b4f-82d7-07917e226aa2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_12bb7589-103a-4c63-9fd5-a1d38a4bafed_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6195a909-73e1-437d-a753-4d57f08ddc36_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_9da1e503-76fe-4745-97b1-d32632739f07_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d5541b0f-060d-49fe-b95f-004cacdde30f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8357b612-21cb-4c9a-8f6f-3b031f20c765_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>imvt-20250206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5236f04c-de75-4016-94d7-a14c75e168f0,g:d73988aa-885e-40a5-9fd8-a2558c6ef7c7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://immunovant.com/role/Cover" xlink:type="simple" xlink:href="imvt-20250206.xsd#Cover"/>
  <link:presentationLink xlink:role="http://immunovant.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cae3fb34-75b1-4750-a94e-771851c32e5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_DocumentType_cae3fb34-75b1-4750-a94e-771851c32e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3ffe8c5a-9ef2-4420-91e3-a06b5c66c847" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_DocumentPeriodEndDate_3ffe8c5a-9ef2-4420-91e3-a06b5c66c847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_037e181e-bf9a-4f02-9f99-e5d5a2314c2e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityRegistrantName_037e181e-bf9a-4f02-9f99-e5d5a2314c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_08a49ff0-62a9-4879-993b-1bad08a4f5f0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_08a49ff0-62a9-4879-993b-1bad08a4f5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5cdbdaba-733b-4a2d-b93c-0c7a3a2c0c64" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityFileNumber_5cdbdaba-733b-4a2d-b93c-0c7a3a2c0c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_344a92d6-0a11-47cc-a518-955c6fa60d0d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityTaxIdentificationNumber_344a92d6-0a11-47cc-a518-955c6fa60d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fd8d5bed-6019-4439-bcc5-68ad6ab3d3bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityAddressAddressLine1_fd8d5bed-6019-4439-bcc5-68ad6ab3d3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_db701e9a-5991-4077-bed4-05aa12acb66a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityAddressCityOrTown_db701e9a-5991-4077-bed4-05aa12acb66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bb1d6af2-54c1-4e4b-b61b-a0e7abb2b003" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityAddressStateOrProvince_bb1d6af2-54c1-4e4b-b61b-a0e7abb2b003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_988b96c4-b2db-4c77-8355-c12f85a50e43" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityAddressPostalZipCode_988b96c4-b2db-4c77-8355-c12f85a50e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fa0e3ec3-34e8-4ab3-ba12-79f06e719139" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_CityAreaCode_fa0e3ec3-34e8-4ab3-ba12-79f06e719139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a2f825cd-d7c6-4400-82a8-30293c3d20b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_LocalPhoneNumber_a2f825cd-d7c6-4400-82a8-30293c3d20b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_47728463-1e81-417e-8a29-d2a1b5b0c985" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_WrittenCommunications_47728463-1e81-417e-8a29-d2a1b5b0c985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3f65536f-0fe4-4f7b-8e43-3519b554151b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_SolicitingMaterial_3f65536f-0fe4-4f7b-8e43-3519b554151b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_919ef95d-266b-4162-b098-93db795d7e09" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_PreCommencementTenderOffer_919ef95d-266b-4162-b098-93db795d7e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_fae25e91-9241-42f0-93bc-f90e61449a85" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_fae25e91-9241-42f0-93bc-f90e61449a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_47e77560-b2ad-42f7-8a5a-3cfc40a8366a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_Security12bTitle_47e77560-b2ad-42f7-8a5a-3cfc40a8366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_053c433b-7a3b-4d0c-be11-de785d6d92a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_TradingSymbol_053c433b-7a3b-4d0c-be11-de785d6d92a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fdc060f3-cfba-4b39-9fd7-5d114e1a2312" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_SecurityExchangeName_fdc060f3-cfba-4b39-9fd7-5d114e1a2312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0c06e15f-457d-404d-a978-8cfef72fcd6d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityEmergingGrowthCompany_0c06e15f-457d-404d-a978-8cfef72fcd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ad44022f-e0a6-4223-8b5f-d119f9cc893d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_EntityCentralIndexKey_ad44022f-e0a6-4223-8b5f-d119f9cc893d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ab8a08ba-71fc-4d53-831b-c7e019ec1f44" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_efcb2cbd-dd68-48e5-b1d4-4d33c42ed1c1" xlink:to="loc_dei_AmendmentFlag_ab8a08ba-71fc-4d53-831b-c7e019ec1f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46005253850416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUNOVANT, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2771572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">320 West 37th Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">580-3099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMVT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001764013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MRN]TO%;'1_!Z.5[O$KQ1&,)$U[6/&_(%OB-/HC2+N&+#=\DKTX8T.F8#I:'
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M,>P'\'XEI?EHV!-K_@^'X7]02P,$%     @ NC1&6I^@&_"Q @  X@P   T
M  !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV
M!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-S
MS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.
MIM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#
M%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6
M#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#H
MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_
MC!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK
M'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?
MK7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*
MLN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-
MM[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]
MK-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7
MCX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L
M"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9G
MD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ NC1&6I>*
MNQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q
M%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(
MMB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!
M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B
M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "Z-$9:JL0B%C,!   B @  #P   'AL+W=O<FMB;V]K+GAM;(U1T6[", S\
ME2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-KY_;JAK27O:4W-FZW%T6%^+3
M@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQF
MN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4[]ST=P<F\1C0XQ7*W&0FB35=
M7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S8@\?5HWD9I:I8(4<I=_H]:UZ
M/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1
MP74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\
M]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ NC1&6B0>
MFZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#
M, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W
M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9
MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ
MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( +HT
M1EIED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%
MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/
M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4
MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N
M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC
M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A
MLO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_
M7G\!4$L! A0#%     @ NC1&6@=!36*!    L0   !               ( !
M     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "Z-$9:>;_@F>\    K
M @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M    " "Z-$9:F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE
M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +HT1EHSU\,R2 0  'P0   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " "Z-$9:GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( +HT1EJ7BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +HT1EJJQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "Z-$9:)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "Z-$9:99!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="imvt-20250206.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immunovant.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="imvt-20250206.htm">imvt-20250206.htm</File>
    <File>imvt-20250206.xsd</File>
    <File>imvt-20250206_lab.xml</File>
    <File>imvt-20250206_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "imvt-20250206.htm": {
   "nsprefix": "imvt",
   "nsuri": "http://immunovant.com/20250206",
   "dts": {
    "inline": {
     "local": [
      "imvt-20250206.htm"
     ]
    },
    "schema": {
     "local": [
      "imvt-20250206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imvt-20250206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imvt-20250206_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://immunovant.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "imvt-20250206.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "imvt-20250206.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001764013-25-000024-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001764013-25-000024-xbrl.zip
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MC")J@0%]!>8%K GW&E',KP635%,ON)XS)YA,N8^VQ46.!CT7!\"8^) (DX]
M\\ * BDC5V J@JDG%)$B!H4EB8RH10:\[?(YV#KT)Z"P4>Y0A"6'0N*_,H(*
M 69DZ+(_4N]"5'L7S7N8EXTMU?YTNI69$_/T=P%L54![!=3_3V6N<6S).#:J
M:Y"$)1;NBIGP@BDI&JB<#[*F7B "_NDB(JI;9M?<\_)^SRDV=.Y00*?[;N(4
MT0Y A>]RZ(?_G4;!):!@2YQN9G 'S<Z&(K)Z]MX-+GYYP2E@L7#&J9:@/+$[
M4/ ^B VT!L@>X1IM<>*1=V-0YUJG+.+@C7P18!R_<>]/D(AOL,OF1=. <5V*
M$0S2PDEB4"KH9O!G .G0W87Y:#)6P 3Z"H;[1)!>TN".OZ(QP@<1$R^S%#+/
M6-DR[2UY6L1V+S\H#TS1D*#J]?Q9)!89/@4* FD0,)Q4:0V%-JBE(Z<X(,!S
M45'>4"#"DDA9EE$"/AJV=QK+"?0,?6D%VF0D2-Y!#!=!S# D#<''!$+0<#QP
M4)F7>ZI&H23-K ,>TEXL%34,XCB8J!#75J4O@=H>\=ZH5W.8!PG,5X'1)?8/
MN.3AY8CZZ[<I8!A[YE)Z(%A 0+2+T :=;0A:#>QH(7R5Z0C9MU'@)!'RCTDP
MPP9FX0NXE?A>X'PG((\2,(\YO!#3."A5HLK(@V!#L-<C&>/3Y8$P@5$KA%;,
MT/*"!4%=P+AOPP6*)/Q\= 2]/D,>)68R2"(/S8H?),#>7*.D_255BE+G@?A^
M;LO)28B8F'$O4;>*40+4E4-+8]4D:!U<<?/@R[)/T&TN!EBUNKQZ^\YW R>4
MJ>'_@N,QG]0CH$?0C)"4WYMG0$(KC.B7810O6-=07,LH#K,0GG)$4X<WY8AI
M5&ZMEB#V7+#Y; KC B'8!Y4B#?EPP6[& 5&>\1P&'7!80XS8N2*:2A@R$/+Y
M-8H<GEU='!?1ER:[PA%'#4G#1'HN:?B2-[X2W*$@#>A;A.%UBM(HK^=F+$$)
MHN3Z&DR?XEVY)4!==X68LH_7'T JR)/0!Y+J:T4\"&0#K2).#$(3U-2TB7X0
MLQN!] NZ"F./RA^")H$)V*.N'2PJP7P%Z4@/5CFS@HP7\3OJ.:(B=_5Q*8"W
M&K\SB@YK5 7P '_RVE^D)@1>9'3+J%BPLA\NP)I?$=.ADHC-E\*!6.TT) A(
M09_Q09V8@^[YJV#:6*6HI'8I+YTJ,[L4#<N&W06ER\R$F(MB?N#JW<6QH6#U
M'?P@"GBHJ82_ M4<QV/N352<S%@@U,.*3A/H'3%X8X2?@P%7H&_$YN!943_B
M=X)L,@$AY$@"U,U8$'Z@V&D21O !Z(SO@@9H8 7C()1_DGFE=I6:"1^&^@.<
M+DJ@!VNG;/ $W&EJF/31U: Z%DC,!*<0^13&\=M+3W%C]YL#B@P&$5F$DU"@
MBS43*U/?V8MI?<SB%3Z, B^)5U^Y8[9<_7<<9B5/^;5H# &"WQM\!/[."?=N
M^#QZ]; S] ?/DSYAZ/E9<"0)Y,!W:2A2<2OTJ>\P6#D_6M1C<*M7XN[-8BY]
M2;47QHPXU_"230%6QD,:T'SQ V4CIE&%^4B]^9*%4 ,;185OHWF9^5@9WBX_
M9"RI)"A5UTA55=%)>-/S@ANL(7U61AC_34)1,5E"XR25_7*'PJ\5DT 8?4FE
MI7!1\NP6^YDB,>O&KPQXRJ4KT'<U#HIPC($C(W%3G!(8HM.:^H9NR&'<5/5*
MAIYT2IVIPI$TNI7FZK$VQGH0WP=VJLBZ@4=B0_0]B0%R;W&A-'%B&QN>-6HU
MVC/DSO?K$'B\VT@K/J+_G3ZNLWLK#',COA@_6>/#<@<)B$&^:L.1<9AX-!<+
M7P$\QP)?+05_P(4]_W)VS!0?F8E-<U=0844^$8S^#&A;7L'<!Q^#"$ =7=3M
MHZYILLGU,>JTD@'+XZ1D= M/%SZ*SBV\B;4K^;=.$!+'@M90:X<BQ@F9/.@D
M)]#(F9KG@Y;BV__%OIX5SF^<YD\J6?GLO?,5O6;*H@O"5<W;&]AI$JQ(;"O%
M0='\O%?34%<T#;5MDMO6TTH/UKYSG O^DE)?FG!\C*E&#&]6SS,76IHCF*:O
MD;;0#_%'(F?H:Y&9!XH%'?"ZW;.;O6P:>AV$-A'_7=;IP?KEZ\\_M?NG%^P=
MC&!^A)EM:[KF,>RGZC.@)(((*R78E:9B1%IGX LPK+X>V,TBH2!WS<<85:%8
M2[1N]M90 <10\8/7X-NU[U-.6UE&L(DA.?TW'&/I,,"'( SF*D)$1AJ40#&4
M*?!Y'A9.=RF>D\3(%99CZN6QH)P<08$\*!N\<3\9P8\D5)<CI%3"$S,U#H@P
M"GQ?>(W,EN8R1.&F-AO,:+@P.:N,/17&LA>A+6OF\);J7"45'+MHP M&(\SE
M!&H(7*G\Z:IO%:/@ES$6965N"E3=#_SEN>1=]/&AU>X#J=W9W6KWX-KU :?X
M4R%R=P(B5 1D)I;URQHT^W7HE]5NMAY,OU((KP>ZP3SP655[E<< O&$D*.:*
M>B?P$>4C*+TLS;(K5.*;*G*&3HLR373GD 'W"6K[:Q ](M"P!A[F:6&_O;8L
MJVGE*#AZ;39[7>PURER *Y0_<+P+S#I6TU[X0'O'#P#^\C9L4R\"S$IA&7=V
M418%B:"'7UMFH2(&H@S=2U!);VZ4C2(8O0:1DPB,\/?&D$<J]0.1KL";HOZ0
MD7FN^N,;-N$ B2&:"*$LH&7WC);9-CK=CH(/O9/A">O/9!0E:7I3D,24M@3C
M\"&+_R['XQ.&&2\5P.MW.S3OW9WWMKJ]"L+J8[]M-R[;W>;@'N5HWON4>:^>
MV-JOO?WXI=+TL,<8]:Z*L<U'%?TCD2%--#<HESZ*"H*[U@9M86^:];9QLS6[
MCR+8"V6&-K2?QCU%G[IEK5+8HV0Y\.,<TWG3H"B8T'(I6&HHKC&/!)?N3/(L
MR^7I.TH>5&17A)-\D=$_N'_F802XX4D'Z\/X-7!A2H8Z8+KS%!WO3J_D*MU_
M?+=;%?&QFH;W@W"[]XFCU32YP\'XH?GZ;;.WX(JWFI9YBRM^#^;:MYMFZ0/6
M[;[^1IA?<?4WJ-:=GGZ[5PJAD:??+D4I'L;3+]C4XE8:.MUIHW2GK<2VWZ5_
M9\,@B5=6]=6TBK'R+7,U-<!N]AYS:46ZDE%&>UQ$V,1H$0<GC$MOZ/$_0==Q
M;AVGW6E2N1BZ*'S$SM.O8RU3"H:?E3XV0<W9QR!ED2:_XWH0M5)D(D2<)[A[
MX@>9C!D,O%!Q,$BTV'5IJ4=E==]#FTJYR^5A-DU23ZMH,"@(!_F9!*W=-W7&
M-<6TJMH53J"B R?$/O&I5V]EL?X,Y+'_NKUZNZ%NF8>U0AAZ_X:';N/7(/B.
MN/L6@P8@3]]P096Y5_U.'5-)ZY#(#5*(Q$@/EVKI'37'2YL3Y<W)A^II$L*P
M(W)?)>(CP8 ## .BG3/*78Q2SP;)[9=TJ?@WX22ABE+]*K,-8]A701EC9PXY
M4=9@T"G1V)%PB<9'Q:L>OTFC/TE$Z5XW00B:&B7HS$79TDF'%^LQTTL3/E^Y
MA%)9OG@#?&'E6I!X[O+%:%QU566K+5\="@]]Q96'HYC6W"]?5PF<RU=QS<3R
MM6*YV/(=E=B:7RV$&DD $P^1U(3*1X@HCT^]D.;QX<X+<C2_!1!-]@UEGC[
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MFRKMNH^F&@NMF^ B%[(7:0BU5!C6"E>Y@42(*^&:%\R!1!..NSA XT%C)%F
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M#EER[*\,+^YUR&P2(_OEY[IEUHX3(EG(AOTX8B12-MT1&KAABC@0\#XI[&+
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M @  \P8  !$   !I;79T+3(P,C4P,C V+GAS9,U46V_:,!1^YU=X>9YS@T!
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MNNG&E9W71NY3&J,V<1^=3;Z!^Y1&U^;MCHU'IU\-#X7F]3PI(112)!$PBF%
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M?1)M?AKG]M'IB^TSZ?J_59Z^^!]02P,$%     @ NC1&6AY_AXJP!@  VC
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M-BYH=&U02P$"% ,4    " "Z-$9:[K7%#*0/  "\:@  $0
M@ '<'@  :6UV="TR,#(U,#(P-BYH=&U02P$"% ,4    " "Z-$9:R^ZS!F$"
M  #S!@  $0              @ &O+@  :6UV="TR,#(U,#(P-BYX<V102P$"
M% ,4    " "Z-$9:" +(- P*  !]5   %0              @ $_,0  :6UV
M="TR,#(U,#(P-E]L86(N>&UL4$L! A0#%     @ NC1&6AY_AXJP!@  VC
M !4              ( !?CL  &EM=G0M,C R-3 R,#9?<')E+GAM;%!+!08
1    !0 % $<!  !A0@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>imvt-20250206_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imvt-20250206.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764013</identifier>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001764013</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-02-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">IMMUNOVANT, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38906</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">83-2771572</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">320 West 37th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">10018</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">917</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">580-3099</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">IMVT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
